Clinical trial · Observational
Changhai Multimodal Esophageal Cancer Cohort
Prediction of Immune Infiltration Level and Immunotherapy Efficacy of Esophageal Squamous Cell Carcinoma Based on Multimodal Deep Learning
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The burden of esophageal squamous cell carcinoma (ESCC) in China is substantial, with 85% of the cancers being in the progressive stage. The treatment for advanced ESCC are extremely limited, and immunotherapy, represented by PD-1 inhibitors, has demonstrated a promising application potential. However, the effectiveness of PD-1 inhibitors varies significantly among patients with different types of ESCC, and currently, there is no effective method to predict the response to PD-1 inhibitors. In this study, investigators aim to construct a multimodal deep learning-based model to predict the level of immune infiltration and the efficacy of immunotherapy for ESCC, integrating both pathological image features and clinical information of patients with ESCC, thereby enhancing the level of individualized and precise treatment for ESCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA Sequencing, RNA Sequencing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- esophageal squamous cell carcinoma
- interventionNames
- Diagnostic Test: DNA Sequencing, RNA Sequencing
Primary outcomes (1)
- measure
- Immunogene signatures with predictive value for immunotherapy of ESCC
- timeFrame
- After undergoes surgery.
Secondary outcomes (1)
- measure
- Prognosis and immunotherapy tolerance in ESCC patients
- timeFrame
- Follow-up for at least 1 year after undergoing surgery
- description
- The prognosis was determined through follow-up, while tolerance to immunotherapy was anticipated utilizing gene sequencing methodologies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Availability of Hematoxylin and Eosin (H\&E) stained images, molecular data obtained through RNA sequencing (RNA-Seq, DNA-seq), and comprehensive clinical information including patient age, gender, history of alcohol consumption, history of smoking, AJCC Tumor, Node, Metastasis Stage, specific location of oesophageal cancer occurrence, and history of reflux. 2. The sample collection is restricted to cancerous tissue, encompassing both primary tumor samples and those from metastatic sites. Exclusion Criteria: 1. Patients diagnosed with adenosquamous carcinoma or presenting with a combination of other types of oesophageal cancers; 2. Cases involving combined adenocarcinoma affecting the gastroesophageal junction; 3. Individuals with high-grade tumors that have not penetrated the basement membrane, as confirmed by postoperative pathological examination; 4. Subjects in whom postoperative pathology confirms an absence of residual malignant tissue.
References
Publications (0)
Data not yet available